Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Adverse events associated with weight-based, high-dose montelukast exposures in children.

Arnold DH, Bowman N, Reiss TF, Hartert TV, Akers WS, Seger DL.

Clin Toxicol (Phila). 2019 May 6:1-2. doi: 10.1080/15563650.2019.1609686. [Epub ahead of print] No abstract available.

PMID:
31056949
2.

Cutting Edge: FHR-1 Binding Impairs Factor H-Mediated Complement Evasion by the Malaria Parasite Plasmodium falciparum.

Reiss T, Rosa TFA, Blaesius K, Bobbert RP, Zipfel PF, Skerka C, Pradel G.

J Immunol. 2018 Dec 15;201(12):3497-3502. doi: 10.4049/jimmunol.1800662. Epub 2018 Nov 19.

PMID:
30455399
3.

Characterization of deproteinized dentin for its use in bone tissue engineering.

Fichant C, David B, Reiss T, Roubier N, Vennat E.

Comput Methods Biomech Biomed Engin. 2017 Oct;20(sup1):73-74. doi: 10.1080/10255842.2017.1382867. No abstract available.

PMID:
29088657
4.

Adverse events are rare after single-dose montelukast exposures in children.

Arnold DH, Bowman N, Reiss TF, Hartert TV, Seger DL.

Clin Toxicol (Phila). 2018 Jan;56(1):25-29. doi: 10.1080/15563650.2017.1337123. Epub 2017 Jun 22.

5.

Interfacial memristors in Al-LaNiO3 heterostructures.

Tian B, Nukala P, Hassine MB, Zhao X, Wang X, Shen H, Wang J, Sun S, Lin T, Sun J, Ge J, Huang R, Duan C, Reiss T, Varela M, Dkhil B, Meng X, Chu J.

Phys Chem Chem Phys. 2017 Jul 5;19(26):16960-16968. doi: 10.1039/c7cp02398g.

PMID:
28636685
6.

Quantitative Study of Interface/Interphase in Epoxy/Graphene-Based Nanocomposites by Combining STEM and EELS.

Liu Y, Hamon AL, Haghi-Ashtiani P, Reiss T, Fan B, He D, Bai J.

ACS Appl Mater Interfaces. 2016 Dec 14;8(49):34151-34158. Epub 2016 Nov 30.

PMID:
27960430
7.

An Official American Thoracic Society Research Statement: Implementation Science in Pulmonary, Critical Care, and Sleep Medicine.

Weiss CH, Krishnan JA, Au DH, Bender BG, Carson SS, Cattamanchi A, Cloutier MM, Cooke CR, Erickson K, George M, Gerald JK, Gerald LB, Goss CH, Gould MK, Hyzy R, Kahn JM, Mittman BS, Mosesón EM, Mularski RA, Parthasarathy S, Patel SR, Rand CS, Redeker NS, Reiss TF, Riekert KA, Rubenfeld GD, Tate JA, Wilson KC, Thomson CC; ATS Ad Hoc Committee on Implementation Science.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1015-1025.

8.

Integrated assessment of emerging science and technologies as creating learning processes among assessment communities.

Forsberg EM, Ribeiro B, Heyen NB, Nielsen RØ, Thorstensen E, de Bakker E, Klüver L, Reiss T, Beekman V, Millar K.

Life Sci Soc Policy. 2016 Dec;12(1):9. doi: 10.1186/s40504-016-0042-6. Epub 2016 Jul 28.

9.

Predictors of asthma following severe respiratory syncytial virus (RSV) bronchiolitis in early childhood.

Lu S, Hartert TV, Everard ML, Giezek H, Nelsen L, Mehta A, Patel H, Knorr B, Reiss TF.

Pediatr Pulmonol. 2016 Dec;51(12):1382-1392. doi: 10.1002/ppul.23461. Epub 2016 May 6.

10.

BEAR Cage: Mentoring through Engagement.

Reiss TF, Moss J, Watkins TR, Malhotra A.

Am J Respir Crit Care Med. 2016 Apr 1;193(7):714-6. doi: 10.1164/rccm.201602-0297ED. No abstract available.

PMID:
26910761
11.

Drug development for airway diseases: looking forward.

Holgate S, Agusti A, Strieter RM, Anderson GP, Fogel R, Bel E, Martin TR, Reiss TF.

Nat Rev Drug Discov. 2015 Jun;14(6):367-8. doi: 10.1038/nrd4645. Epub 2015 May 22.

PMID:
26000726
12.

The development of synthetic biology: a patent analysis.

van Doren D, Koenigstein S, Reiss T.

Syst Synth Biol. 2013 Dec;7(4):209-20. doi: 10.1007/s11693-013-9121-7. Epub 2013 Aug 22.

13.

The asthma disease activity score: a discriminating, responsive measure predicts future asthma attacks.

Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen L, Gates DF Jr, Kuo WL, Smugar SS, Reiss TF, Barnes N, Fuhlbrigge A, Milgrom H, Schatz M, Knorr B.

J Allergy Clin Immunol. 2012 Nov;130(5):1071-1077.e10. doi: 10.1016/j.jaci.2012.07.057. Epub 2012 Oct 1.

PMID:
23036744
14.

Special issue - synthetic biology.

Reiss T.

FEBS Lett. 2012 Jul 16;586(15):2027-8. doi: 10.1016/j.febslet.2012.06.001. Epub 2012 Jun 9. No abstract available.

15.

Collaborative science and the American Thoracic Society: cooperation in harmony with conflict of interest.

Reiss TF, Moss J, Osborne M, Curtis JR, Hill NS.

Am J Respir Crit Care Med. 2012 Feb 15;185(4):347-9. doi: 10.1164/rccm.201110-1824ED. No abstract available.

16.

Airway obstruction lability helps distinguish levels of disease activity in asthma.

Greenberg S, Liu N, Kaur A, Lakshminarayanan M, Zhou Y, Nelsen LM, Smugar SS, Noonan G, Reiss TF, Knorr BA.

Respir Med. 2012 Apr;106(4):500-7. doi: 10.1016/j.rmed.2011.12.013. Epub 2012 Jan 31.

17.

The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma.

Wasfi YS, Villarán C, de Tilleghem Cle B, Smugar SS, Hanley WD, Reiss TF, Knorr BA.

Respir Med. 2012 Jan;106(1):34-46. doi: 10.1016/j.rmed.2011.08.019. Epub 2011 Sep 25.

18.

Intermittent or daily montelukast versus placebo for episodic asthma in children.

Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen LM, Knorr BA, Reiss TF, Philip G, Gurner DM.

Ann Allergy Asthma Immunol. 2011 Jun;106(6):518-26. doi: 10.1016/j.anai.2011.01.017. Epub 2011 Mar 4.

PMID:
21624752
19.

The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma.

Philip G, Villarán C, Shah SR, Vandormael K, Smugar SS, Reiss TF.

J Asthma. 2011 Jun;48(5):495-502. doi: 10.3109/02770903.2011.573042. Epub 2011 May 5.

PMID:
21545249
20.

MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.

Bernstein JA, Liu N, Knorr BA, Smugar SS, Hanley WD, Reiss TF, Greenberg S.

Respir Med. 2011 Mar;105(3):392-401. doi: 10.1016/j.rmed.2010.09.021. Epub 2010 Nov 13.

21.

A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma.

Philip G, Pedinoff A, Vandormael K, Tymofyeyev Y, Smugar SS, Reiss TF, Korenblat PE.

J Asthma. 2010 Dec;47(10):1078-84. doi: 10.3109/02770903.2010.520100. Epub 2010 Nov 3.

PMID:
20936994
22.

A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.

Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S.

J Urol. 2010 Aug;184(2):616-22. doi: 10.1016/j.juro.2010.03.147. Epub 2010 Jun 19.

PMID:
20639026
23.

Enantioselective total synthesis of the unnatural and the natural stereoisomers of vittatalactone.

Schmidt Y, Lehr K, Breuninger U, Brand G, Reiss T, Breit B.

J Org Chem. 2010 Jul 2;75(13):4424-33. doi: 10.1021/jo100383u.

PMID:
20527973
24.

A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma.

Camargo CA Jr, Gurner DM, Smithline HA, Chapela R, Fabbri LM, Green SA, Malice MP, Legrand C, Dass SB, Knorr BA, Reiss TF.

J Allergy Clin Immunol. 2010 Feb;125(2):374-80. doi: 10.1016/j.jaci.2009.11.015.

PMID:
20159247
25.

Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis.

Lu S, Malice MP, Dass SB, Reiss TF.

J Asthma. 2009 Nov;46(9):878-83. doi: 10.3109/02770900903104540.

PMID:
19905912
26.

Shaping the science-industry-policy interface in synthetic biology.

Gaisser S, Reiss T.

Syst Synth Biol. 2009 Dec;3(1-4):109-14. doi: 10.1007/s11693-009-9027-6. Epub 2009 Oct 10.

27.

Analysis of behavior-related adverse experiences in clinical trials of montelukast.

Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, Knorr B.

J Allergy Clin Immunol. 2009 Oct;124(4):699-706.e8. doi: 10.1016/j.jaci.2009.08.011. Erratum in: J Allergy Clin Immunol. 2010 May;125(5):1019.

PMID:
19815116
28.

Reports of suicidality in clinical trials of montelukast.

Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B.

J Allergy Clin Immunol. 2009 Oct;124(4):691-6.e6. doi: 10.1016/j.jaci.2009.08.010.

PMID:
19815114
29.

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.

Philip G, van Adelsberg J, Loeys T, Liu N, Wong P, Lai E, Dass SB, Reiss TF.

J Allergy Clin Immunol. 2009 Nov;124(5):942-8.e1-9. doi: 10.1016/j.jaci.2009.07.006. Epub 2009 Sep 12.

PMID:
19748656
30.

Total synthesis of (+)-bourgeanic acid utilizing o-DPPB-directed allylic substitution.

Reiss T, Breit B.

Org Lett. 2009 Aug 6;11(15):3286-9. doi: 10.1021/ol9011635.

PMID:
19719180
31.

Making the most of synthetic biology. Strategies for synthetic biology development in Europe.

Gaisser S, Reiss T, Lunkes A, Müller KM, Bernauer H.

EMBO Rep. 2009 Aug;10 Suppl 1:S5-8. doi: 10.1038/embor.2009.118. No abstract available.

32.
33.
34.

Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions.

Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Noonan G.

Pediatr Pulmonol. 2009 Jun;44(6):568-79. doi: 10.1002/ppul.21018. Review.

PMID:
19449366
35.

Montelukast and bronchial inflammation in asthma: a randomised, double-blind placebo-controlled trial.

Ramsay CF, Sullivan P, Gizycki M, Wang D, Swern AS, Barnes NC, Reiss TF, Jeffery PK.

Respir Med. 2009 Jul;103(7):995-1003. doi: 10.1016/j.rmed.2009.01.019. Epub 2009 Feb 26.

36.

Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma.

Lu S, Liu N, Dass SB, Reiss TF, Knorr BA.

Respir Med. 2009 Mar;103(3):342-7. doi: 10.1016/j.rmed.2008.10.024. Epub 2009 Jan 8.

37.

Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children.

Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal JL, Dass SB, Reiss TF, Knorr BA.

Am J Respir Crit Care Med. 2008 Oct 15;178(8):854-60. doi: 10.1164/rccm.200706-910OC. Epub 2008 Jun 26.

PMID:
18583576
38.

Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis.

Kearns GL, Lu S, Maganti L, Li XS, Migoya E, Ahmed T, Knorr B, Reiss TF.

J Clin Pharmacol. 2008 Apr;48(4):502-11. doi: 10.1177/0091270008314251. Epub 2008 Feb 22.

PMID:
18296556
39.

Comparisons of aprepitant and ondansetron.

Carides A, Reiss T, Lines C, McKeon B, Diemunsch P.

Am J Health Syst Pharm. 2007 Dec 1;64(23):2422-4; author reply 2424-6. No abstract available.

PMID:
18029945
40.

Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant.

Diemunsch P, Apfel C, Gan TJ, Candiotti K, Philip BK, Chelly J, Carides AD, Evans JK, Ho TW, Reiss T.

Curr Med Res Opin. 2007 Oct;23(10):2559-65.

PMID:
17845742
41.

Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children.

Pedersen S, Agertoft L, Williams-Herman D, Kuznetsova O, Reiss TF, Knorr B, Dass SB, Wolthers OD.

Pediatr Pulmonol. 2007 Sep;42(9):838-43.

PMID:
17659605
42.

Efficacy of montelukast for treating perennial allergic rhinitis.

Philip G, Williams-Herman D, Patel P, Weinstein SF, Alon A, Gilles L, Tozzi CA, Dass SB, Reiss TF.

Allergy Asthma Proc. 2007 May-Jun;28(3):296-304.

PMID:
17619558
43.

Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction.

Philip G, Pearlman DS, Villarán C, Legrand C, Loeys T, Langdon RB, Reiss TF.

Chest. 2007 Sep;132(3):875-83. Epub 2007 Jun 15.

PMID:
17573489
44.

Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.

Diemunsch P, Gan TJ, Philip BK, Girao MJ, Eberhart L, Irwin MG, Pueyo J, Chelly JE, Carides AD, Reiss T, Evans JK, Lawson FC; Aprepitant-PONV Protocol 091 International Study Group.

Br J Anaesth. 2007 Aug;99(2):202-11. Epub 2007 May 30.

45.

Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast.

Philip G, Villarán C, Pearlman DS, Loeys T, Dass SB, Reiss TF.

J Asthma. 2007 Apr;44(3):213-7.

PMID:
17454341
46.

Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.

Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF.

J Urol. 2006 Dec;176(6 Pt 1):2535-40; discussion 2540.

PMID:
17085151
47.

Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast.

Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, Loeys T, Dass SB, Reiss TF.

Ann Allergy Asthma Immunol. 2006 Jul;97(1):98-104.

PMID:
16892789
48.

An oral selective M3 cholinergic receptor antagonist in COPD.

Lu S, Parekh DD, Kuznetsova O, Green SA, Tozzi CA, Reiss TF.

Eur Respir J. 2006 Oct;28(4):772-80. Epub 2006 Jul 26.

49.

Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study.

Becker AB, Kuznetsova O, Vermeulen J, Soto-Quiros ME, Young B, Reiss TF, Dass SB, Knorr BA; Pediatric Montelukast Linear Growth Study Group.

Ann Allergy Asthma Immunol. 2006 Jun;96(6):800-7.

PMID:
16802767
50.

Exploring the limits of polarization transfer efficiency in homonuclear three spin systems.

Neves JL, Heitmann B, Reiss TO, Schor HH, Khaneja N, Glaser SJ.

J Magn Reson. 2006 Jul;181(1):126-34. Epub 2006 Apr 27.

PMID:
16644249

Supplemental Content

Support Center